| Matrixx Initiatives Inc. F4Q10 (Qtr End 3/31/10) Earnings Call Transcript Matrixx Initiatives Inc. (MTXX)F4Q10 Earnings CallMay 11, 2010 11:00 am ETComplete Story » seekingalpha.com |
Eating to Live or Living to Eat? Seeing pictures of sweet and fatty foods can entice obese people to overeat, even when they're full, research in brain-imaging shows. online.wsj.com |
NEJM Editorial Raises Questions About Dendreon’s Cancer Vaccine Study: Biotech's Latest Mishaps The Burrill Report submits: A New England Journal of Medicine editorial is raising questions about a pivotal study of Dendreon’s (DNDN) prostate cancer vaccine Provenge. The study found that the vaccine extended survival by 4.1 months compared to placebo in men with prostate cancer that had spread who do not respond to hormone therapy. What’s raised questions about the Provenge study is that it showed no measurable effect on tumors. An editorial that ran with the study called that “surprising” and said "it is hard to understand how the natural history of a cancer can be affected without some apparent measurable change in the tumor.” It went on to suggest that the lack of tumor effect could indicate that “the results could have been influenced by an unmeasured prognostic variable that was accidentally imbalanced in study-group assignments. The U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that found Eli Lilly’s (LLY) method-of-use patent on its cancer drug Gemzar was invalid. The patent wasn’t set to expire until mid-2013. Lilly said it strongly disagrees with the ruling and is considering legal options. Lilly said in light of the ruling it expects to maintain market exclusivity for Gemzar until November 15, 2010, but the decision will force it to modify its current 2010 financial guidance. Global sales of Gemzar were nearly $1.4 billion in 2009.Complete Story » seekingalpha.com |
ESF: New skills for older workers - Video If you’re seeking a strong human interest story, then take a look at the European Social Fund. Far from being a set of dry statistics, the ESF is the framework for thousands of fascinating tales of individual human endeavour. feedproxy.google.com |
Is Titan Pharmaceuticals Finally Lining Up With the Big Boys? VFC submits: Titan Pharmaceuticals (TTNP.OB) has been on the rise over the past trading week, having hovered around the one dollar mark for some time. This, of course, seems decades away from the time that had TTNP trading for a couple of pennies before rocketing to the mid $2 range, although that event took place only last year, and made patient investors a killing. It looks like things could be heating up again, and TTNP may be ready to return some additional significant returns as Fanapt sales gain steam and the Probuphine trial winds down. The recent rise of the VNDA share price may be offering us a clue as to what Fanapt is doing on the market, and an article published in the Journal of the American Medical Association (JAMA) regarding Probuphine Phase III data could be an indicator that Titan is finally lining up alongside the big players in the medical community.Complete Story » seekingalpha.com |